Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Inclusion Criteria: * Subfoveal CNV due to presumed ocular histoplasmosis of less than 1 year duration * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age greater than or equal to 21 years of age * CNV lesion of than \< 5400 microns in diameter * Best corrected visual acuity of 20/40-20/320 * Birth control therapy for females of child-bearing potential Exclusion Criteria: * Subfoveal NCV due tp presumed ocular histoplasmosis for \> 1 year * Pregnancy or lactation premenopausal women not using adequate contraception * Prior enrollment in the study * Any other condition that the Investigator believes would pose a significant hazard to the subject * Participation in another simultaneous medical investigation or trial * Participation in another trial or previous trial of ranibizumab or Avastin * Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that could require medical or surgical intervention or ifa allowed to progress, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period * Previous panretinal photocoagulation * Previous steroids or PDT in 3 months * Previous participation in any studies of investigational drugs within 30 days preceding Day 0 * Prior participation in a Genentech ranibizumab clinical trial * Previous treatment with intravitreally (in either eye) or intravenously administered Avastin within 3 months * Previous use of Macugen in the study eye within 3 months * Prior submacular surgery